Clinical trials: ST Elevation Acute Myocardial Infarction
Acute Myocardial Infarction
A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks
The primary objective of this study is to gather preliminary data regarding the angiographic efficacy of the administration of low-dose adjunctive intracoronary (IC) tenecteplase during balloon angioplasty for heart attacks.
- Trial name
- ICE T-TIMI 49 (NCT00604695)
- Testing
- Tenecteplase, Sterile Saline
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- C. Michael Gibson, MS, MD
Acute Coronary Syndrome
European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary…
- Trial name
- EUROMAX (NCT01087723)
- Testing
- Bivalirudin, Heparin
- Where
- 145 sites in Austria, Czechia and 7 more
- Volunteers
- 2,198 people
- Sponsor
- The Medicines Company
ST Segment Elevation Acute Myocardial Infarction
Anakinra to Prevent Post-infarction Remodeling
Thousands of patients die daily from early and late complications of a heart attack (acute myocardial infarction, AMI). Patients surviving AMI remain at high risk of death from adverse cardiac remodeling (dysfunction and…
- Trial name
- VCU-ART (NCT00789724)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Myocardial Ischemia, Acute Coronary Syndrome
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention…
- Trial name
- NCT00089895
- Testing
- Eptifibatide (Integrilin)
- Volunteers
- 9,406 people
- Sponsor
- Organon and Co
Acute ST Elevation Myocardial Infarction
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
- Trial name
- NCT00378352
- Testing
- Epoetin alfa
- Where
- 16 sites in United States
- Volunteers
- 223 people
- Sponsor
- National Institute on Aging (NIA)
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Acute ST Elevation Myocardial Infarction
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial.
- Trial name
- HEAT-PPCI (NCT01519518)
- Testing
- unfractionated heparin, Bivalirudin
- Where
- United Kingdom
- Volunteers
- 1,829 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
Myocardial Infarction, Reperfusion Injury
Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries.
- Trial name
- NCT00265239
- Testing
- edaravone
- Where
- Japan
- Volunteers
- 104 people
- Sponsor
- Kumamoto University
Post Procedural Myocardial Infarction
Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
This study investigates the cardioprotective effect of remote ischaemic pre-/postconditioning in patients presenting with a NSTEMI/Unstable angina undergoing PCI.
- Trial name
- NCT03726164
- Testing
- Remote Conditioning
- Volunteers
- 626 people
- Sponsor
- University College, London
Reperfusion Injury, STEMI
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also…
- Trial name
- EMBRACE (NCT01572909)
- Testing
- Bendavia (MTP-131)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Stealth BioTherapeutics Inc.
Unstable Angina, Myocardial Infarction
Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes
The timing of intervention study is a prospective, randomized, international, multicentre comparison of the relative efficacy, safety, and cost effectiveness of a management strategy of coronary angiography and intervention…
- Trial name
- TIMACS (NCT00552513)
- Testing
- Early Coronary Intervention, Delayed Coronary Intervention
- Where
- Canada
- Volunteers
- 3,031 people
- Sponsor
- Population Health Research Institute
Cardiogenic Shock, Acute Myocardial Infarction
National Cardiogenic Shock Initiative
This study evaluates the use of early mechanical circulatory support in patients presenting with acute myocardial infarction and cardiogenic shock.
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCSI (NCT03677180)
- Where
- 75 sites in United States
- Volunteers
- 406 people
- Sponsor
- Henry Ford Health System
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients…
- Trial name
- NCT00433966
- Testing
- Bivalirudin, Unfractionated heparin, Bare metal stent
- Where
- United States
- Volunteers
- 3,602 people
- Sponsor
- Cardiovascular Research Foundation, New York
Acute ST Segment Elevation Myocardial Infarction
Platelet Function in Resuscitated Patients
Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab.
- Trial name
- NCT02914795
- Testing
- diagnostic analysis of platelet function
- Where
- Austria
- Volunteers
- 99 people
- Sponsor
- Medical University of Graz
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Infarction, Myocardial
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Multinational, multicentre, randomised, prospective, open, parallel group study directly comparing two glycoprotein-IIb/IIIa inhibitors, abciximab and eptifibatide, added early to standard treatment before primary PCI of STEMI…
- Trial name
- NCT00426751
- Testing
- Abciximab, Eptifibatide
- Where
- 24 sites in France, Germany
- Volunteers
- 429 people
- Sponsor
- GlaxoSmithKline